Prescribing & Controlled Substance Management

MANDATORY

5 criteria

ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Blocks accreditation until resolved.

REFERENCES

1. [21] Telemedicine prescribing regulations for controlled substances remain an actively evolving area of law in numerous countries, with the underlying international framework under the Single Convention on Narcotic Drugs (1961, as amended) requiring national implementation that can itself change, making active tracking of current, jurisdiction-specific requirements a genuine, ongoing necessity.

Requirements for prescribing controlled substances via telemedicine — including whether an initial in-person evaluation is required — are genuinely still evolving in many countries, and a service that treats a current flexibility or exception as a permanent, settled rule risks continuing a prescribing practice that becomes genuinely non-compliant the moment the relevant regulation changes.

1 Leadership is aware of the current temporary status but this awareness hasn't been specifically communicated to prescribing providers.

Every provider actually prescribing controlled substances needs the same genuine, current awareness.

2 Monitoring happens informally but isn't assigned as a specific, accountable responsibility.

A specific, accountable monitoring responsibility is more reliable than informal, diffuse awareness.

3 The service tracks the current regulatory status but hasn't built a specific contingency plan for if a flexibility lapses without renewal.

Genuine preparedness includes a real plan for the possibility of non-renewal, not only awareness of the current status.

Week 1 Confirm the service's current, specific knowledge of the applicable requirements' status in this jurisdiction.

Week 2 Assign specific, accountable responsibility for monitoring regulatory status changes.

Week 3 Communicate current temporary status clearly to all prescribing providers.

Ongoing Build a contingency plan for a potential lapse in the temporary extension.

Ask a provider directly what the current status of the relevant telemedicine prescribing flexibility is in this jurisdiction.

A specific, accurate answer reveals genuine, current awareness, not an assumption of permanence.

Ask who is specifically responsible for monitoring this regulatory status.

A specific, confident answer reveals a real, accountable process, not diffuse or assumed awareness.

ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Blocks accreditation until resolved.

REFERENCES

1. [22] The Single Convention on Narcotic Drugs (1961, as amended), ratified by 186 countries, establishes that the production, distribution, and use of controlled substances must be limited exclusively to medical and scientific purposes, a principle applying identically whether a prescription is issued in person or via telemedicine.

This requirement traces to the foundational international drug control framework itself, not merely a national policy choice, and it applies identically to remote and in-person prescribing — meaning a service can't treat telemedicine's convenience as license to be less rigorous about verifying genuine medical necessity behind every controlled substance prescription it issues.

1 Documentation is thorough for new prescriptions but less rigorous for ongoing refills of existing prescriptions.

Genuine, continued medical necessity deserves the same documentation rigor at refill as at initial prescribing.

2 Rigor is generally equivalent but providers report feeling more rushed during high-volume remote scheduling.

Genuine rigor shouldn't erode under scheduling pressure, remote or in-person.

3 A pattern review process exists but hasn't identified or addressed any real concern to date.

An untested process, or the honest absence of findings, still deserves genuine confidence it would function if needed.

Week 1 Review current prescription documentation for genuine, specific medical necessity evidence.

Week 2 Reinforce documentation standards for refills, not only initial prescriptions.

Week 3 Establish a genuine pattern review process for prescribing across the service.

Ongoing Address any scheduling pressure that risks eroding prescribing rigor.

Ask to see the actual documented medical necessity for a specific, real controlled substance prescription.

A real, specific example reveals genuine documentation practice, not an assumption of adequacy.

Ask how the service would identify a concerning prescribing pattern if one existed.

A specific, confident answer reveals a genuine, real process, not passive trust alone.

ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Blocks accreditation until resolved.

REFERENCES

1. [23] In countries with federal, provincial, or similarly devolved governance structures, sub-national controlled substance telemedicine prescribing rules can apply independently of and in addition to national requirements, with some regions imposing distinct exceptions or conditions beyond the national baseline.

National-level flexibility doesn't override a region or province's own, separate requirements where such sub-national authority exists, and a service that only tracks national rules may be missing a genuine, additional regional requirement — like a specific region's own recent-in-person-evaluation exception criteria — that applies independently of whatever national flexibility is currently in effect.

1 Sub-national verification happens for regions with the highest patient volume but not for less frequent regions.

Every region where a patient is genuinely located carries the same real requirement, regardless of patient volume.

2 Verification was thorough at initial setup but hasn't been reconfirmed as regional regulations have since evolved.

Regional requirements genuinely change, and verification should reflect current, not historical, regulation.

3 Awareness of a stricter regional requirement exists but isn't consistently, practically applied in actual prescribing.

Genuine awareness needs to translate into consistent, real practice, not remain theoretical.

Week 1 Review current practice for genuine sub-national verification alongside national compliance.

Week 2 Establish specific verification for every region where patients are genuinely located, where such regional authority exists.

Week 3 Build a process for identifying and applying the more restrictive standard where regional and national rules differ.

Ongoing Reconfirm sub-national requirements as regulations evolve.

Ask how the service verifies controlled substance requirements for a specific, less common patient region.

A specific, confident answer reveals genuine, comprehensive verification, not coverage limited to high-volume regions.

Ask for a real example of a regional requirement stricter than the national baseline and how it's actually applied.

A real, specific example reveals whether the more restrictive standard genuinely governs practice.

ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Blocks accreditation until resolved.

REFERENCES

1. [24] Some jurisdictions permit a narrow exception for prescribing certain restricted stimulant medications to minors using real-time, interactive audio-visual technology and prior written guardian consent, in place of the standard in-person evaluation requirement; where no such exception exists in a given jurisdiction, the standard requirement applies without exception.

Where this kind of exception exists at all, it's deliberately narrow and specific, applying only to a particular medication class, a particular patient population, and only when specific conditions are genuinely satisfied — treating it as a general allowance for prescribing to minors without meeting the exact requirements risks genuinely exceeding what a limited exception actually permits, and assuming such an exception exists where it doesn't is its own serious error.

1 Consent is obtained but not consistently documented as specifically written and prior to the prescription.

The exception's specific requirement is prior written consent, and documentation should genuinely reflect this exact standard.

2 Technology modality is generally real-time but isn't specifically verified as meeting the interactive audio-visual requirement.

Genuine verification of the specific technology standard matters as much as general real-time capability.

3 The exception is correctly applied for restricted stimulants but staff aren't fully clear it doesn't extend to other medication classes.

Clear, genuine understanding of this exception's exact scope prevents its accidental extension to prescriptions it doesn't actually cover.

Week 1 Review current practice for genuine adherence to this exception's specific requirements.

Week 2 Confirm technology modality and consent documentation specifically meet the exact exception standard.

Week 3 Train providers on the exception's genuine, narrow scope, not broader application.

Ongoing Audit compliance for every use of this specific exception.

Ask to see the actual, written parental consent document for a real, recent case using this exception.

A real, specific document reveals genuine compliance, not an assumption consent was obtained appropriately.

Ask a provider to describe exactly which medications and patients this exception genuinely applies to.

A specific, accurate answer reveals genuine understanding of the exception's actual, narrow scope.

ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Requires improvement plan.

REFERENCES

1. [25] Under the international framework established by the Single Convention on Narcotic Drugs, each country designates a competent national authority responsible for controlled substance prescribing authorization, with this authorization status forming the foundational basis for lawful prescribing, requiring genuine, periodic verification distinct from a one-time historical check assumed to remain accurate indefinitely.

A lapsed or restricted controlled substance prescribing authorization would mean a provider genuinely lacks the authority to prescribe controlled substances at all, and a service that doesn't actively, periodically verify this status has no real way of knowing whether every controlled substance prescription it's issuing is being issued by someone who's currently, genuinely authorized to do so.

1 Verification happens for full-time prescribing providers but less consistently for occasional or covering providers.

Every provider actually prescribing controlled substances carries the same real requirement for current, verified registration.

2 Verification is reconfirmed periodically but the interval is long enough that a genuine lapse could go uncaught for a meaningful time.

A genuinely protective interval catches a lapse before it affects a meaningful number of prescriptions.

3 A prevention process exists but hasn't been specifically tested against a real, identified registration issue.

An untested process may not reliably catch a genuine registration issue when one actually occurs.

Week 1 Review current authorization verification practice for genuine currency and consistency.

Week 2 Establish a regular, periodic reconfirmation schedule covering all prescribing providers.

Week 3 Build a specific, enforced prevention process for identified registration issues.

Ongoing Extend verification consistently to occasional and covering providers.

Ask to see the actual, current authorization verification for a specific prescribing provider.

A real, specific, current record reveals genuine verification, not an assumption of continued validity.

Ask what would happen if a provider's registration were found to have lapsed.

A specific, confident answer reveals a genuine, enforced prevention process.